Therefore, we concluded that HSF1 is a promising therapeutic target and KRIBB11 or emetine can be used as a lead compound to develop a therapeutic drug for overcoming EGFR-TKIs resistance in NSCLC. This evidence concerns the gene HSF1 and non-small cell lung carcinoma.